Published • loading... • Updated
Topline Phase 3 Data Show Adding Epcoritamab to Standard R-CHOP Cut Lymphoma Progression or Death Risk by 51%
The late-stage trial was the first to show a statistically significant progression-free survival benefit for a bispecific antibody combination in frontline DLBCL.
- On Monday, October 5, 2026, Genmab and AbbVie announced positive Phase 3 results from the EPCORE DLBCL-2 trial, showing epcoritamab combined with R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma .
- Epcoritamab is an immune-based therapy that helps T cells attack cancer cells, addressing a critical need for additional frontline treatment options for approximately 25,000 new DLBCL cases diagnosed annually in the United States.
- The combination reduced the risk of disease progression or death by 51% compared with R-CHOP alone, with a hazard ratio of 0.49 and a p-value of less than 0.0001, according to the companies.
- Dr. Gilles Salles, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, called the results "clinically meaningful" and "highly relevant to everyday practice," signaling potential to reshape frontline treatment.
- Genmab and AbbVie will engage global regulatory authorities to determine next steps for the investigational combination, as the companies work to bring this potential practice-changing therapy to patients.
Insights by Ground AI
24 Articles
24 Articles
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in a late-stage study.
·London, United Kingdom
Read Full Article
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patientsBased on the topline results, Genmab…
Coverage Details
Total News Sources24
Leaning Left2Leaning Right4Center9Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
13%
C 60%
R 27%
Factuality
To view factuality data please Upgrade to Premium
